Breaking News: Class Action Lawsuit Filed Against Cerevel Therapeutics
Los Angeles, CA – April 14, 2025
Investors who purchased Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE) shares between October 11, 2023, and August 1, 2024, or held shares as of the January 8, 2024, record date and were entitled to vote on the merger with AbbVie Inc., and/or sold shares contemporaneously with Bain Capital Investors, LLC’s purchase on or about October 16, 2023, are encouraged to contact The Schall Law Firm
Background on the Class Action Lawsuit
The Schall Law Firm, a national shareholder rights litigation firm, has announced a class action lawsuit against Cerevel Therapeutics for violations of ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission (SEC).
Allegations in the Lawsuit
The complaint alleges that Cerevel made false and misleading statements and failed to disclose material information during the Class Period. Specifically, the Company misrepresented the safety and efficacy of its investigational drug, CER-101, and failed to disclose that the FDA had requested additional data regarding the drug’s clinical trials. As a result, investors suffered significant losses when the truth was revealed.
Impact on Individual Investors
If you are an affected investor, you may be entitled to recover your investment losses. The Schall Law Firm encourages investors to contact the firm before June 3, 2025, to discuss their legal rights and potential remedies. You may be able to join a class action lawsuit to recover your losses or opt-out to pursue other remedies.
Impact on the World
The class action lawsuit against Cerevel Therapeutics could have far-reaching implications for the biotech industry and the broader investment community. The case highlights the importance of transparency and accuracy in the disclosure of clinical trial data and regulatory communications. It also underscores the need for investors to remain vigilant about potential securities fraud and to seek legal recourse when they believe they have been harmed.
Conclusion
The Schall Law Firm’s class action lawsuit against Cerevel Therapeutics is a reminder that investors must be diligent in their research and analysis of publicly traded companies. The lawsuit also underscores the importance of transparency and accuracy in disclosing clinical trial data and regulatory communications. Affected investors are encouraged to contact The Schall Law Firm to discuss their legal rights and potential remedies.
- Cerevel Therapeutics faces a class action lawsuit for securities fraud
- The lawsuit alleges false and misleading statements regarding CER-101
- Investors who purchased shares during the Class Period or held shares as of the record date may be entitled to recover their losses
- The lawsuit highlights the importance of transparency and accuracy in clinical trial data and regulatory communications
